Fludrocortisone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Fludrocortisone
- Fludrocortisone: From Mineralocorticoid Replacement to Primary Cutaneous T-Cell Lymphoma
Fludrocortisone: From Mineralocorticoid Replacement to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Fludrocortisone is a synthetic corticosteroid with mainly mineralocorticoid activity, registered in Singapore as Florinef tablets. The TxGNN model ranks primary cutaneous T-cell lymphoma as its top predicted new indication, but no clinical trials and no publications support it. The prediction rests on model output alone and is likely a class-level artifact of the knowledge graph.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (fludrocortisone's established uses are adrenal insufficiency and orthostatic hypotension) |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Fludrocortisone is a mineralocorticoid with some glucocorticoid activity. Its efficacy in its established uses is documented in the literature compiled for this report. Whether that translates to primary cutaneous T-cell lymphoma is unproven.
Corticosteroids suppress lymphocytes, and topical steroids are used in early-stage cutaneous T-cell lymphoma. However, no specific link to fludrocortisone is documented. The very high score most likely reflects class-level proximity in the knowledge graph rather than a true therapeutic relationship.
The other top-ranked predictions are similarly weak. Cystic teratoma, spinal cord dermoid cyst, dermoid cyst of ovary, exostosis and granulomatous slack skin disease have no plausible mechanistic link. Two broad orbital categories and optic papillitis have no supporting studies either.
The one prediction with some literature is eye disease (rank 6, score 99.14%, evidence level L4). The most relevant item is a 2021 preclinical study showing anti-inflammatory and neuroprotective effects of fludrocortisone in retinal degeneration. A 2022 Phase 1B study also tested intravitreal fludrocortisone acetate for safety and tolerability in geographic atrophy. Because "eye disease" is too broad, a specific indication such as geographic atrophy would need to be defined first.
Clinical Trial Evidence
Currently no related clinical trials registered for primary cutaneous T-cell lymphoma.
Literature Evidence
Currently no related literature available for primary cutaneous T-cell lymphoma.
For reference, the closest literature for the eye disease prediction (rank 6) is:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34509498 | 2021 | Preclinical | Experimental Eye Research | Fludrocortisone showed anti-inflammatory and neuroprotective effects on retinal Müller cells in retinal degeneration |
| 36161841 | 2022 | Phase 1B study | BMJ Open Ophthalmology | Safety and tolerability of single intravitreal fludrocortisone acetate (1 mg and 2 mg) in geographic atrophy |
| 11008895 | 1999 | Clinical study | International Ophthalmology | Fludrocortisone for systemic hypotension in primary open-angle glaucoma patients |
| 17998043 | 2007 | Review | Survey of Ophthalmology | Non-IOP-lowering glaucoma approaches, including fludrocortisone to avoid blood pressure dips |
| 23430676 | 2013 | Review | Klinische Monatsblätter für Augenheilkunde | Non-IOP-lowering glaucoma therapy, including fludrocortisone |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10680P | FLORINEF TABLET 0.1 mg | Tablet | Not recorded in the licence data |
Safety Considerations
- Drug Interactions: 100 interactions were identified. Most are Moderate, and one listed is Major.
- Major: bupropion.
- Moderate, antidiabetic agents (the glucose-raising effect of corticosteroids may reduce their efficacy): acarbose, albiglutide, alogliptin, pioglitazone, canagliflozin, chlorpropamide, dapagliflozin, dulaglutide, empagliflozin, linagliptin.
- Moderate, others: amphotericin B (including lipid complex), aprepitant, acetylsalicylic acid, bisacodyl, picosulfuric acid, clarithromycin, oxandrolone, oxymetholone.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for primary cutaneous T-cell lymphoma is model output only (L5). No trials or publications support it, and no mechanism specific to fludrocortisone is documented. The only tentative signal is in the eye, where preclinical and early-phase work in retinal degeneration/geographic atrophy exists. It is not part of the top-ranked prediction.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently a blocking gap for safety screening)
- Detailed mechanism of action data (MOA)
- Approved indication text for the Singapore licence
- For the lymphoma prediction: a mechanistic rationale and preclinical data specific to fludrocortisone
- For the eye signal: a defined target indication (e.g., geographic atrophy), full-text review of the key papers, and a decision on whether to treat it as a separate research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.